Zhao Chuanbing

Dr. Zhao Chuanbing

Renmin Hospital of Wuhan University, Wuhan, Hubei, China

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 September 2022 in Current Oncology
Verified
Journal Article
Open access
PDF file
ZCZhao Chuanbing
Zhao Chuanbing
ZZZhengle Zhang
Zhengle Zhang
TJTao Jing
Tao Jing
Hepatocellular carcinoma (HCC) is a malignant disease with an increasing incidence and a high mortality rate. Ferroptosis, a novel type of cell death, has been reported to be closely associated with the progression of HCC. The aim of our study was to construct a novel ferroptosis-related signature (nFRGs) for prediction of prognosis, immune features and drug sensitivity of HCC patients. Data were obtained from the TCGA, ICGC, GSE104580, CCLE and IMvigor210 datasets, and the least absolute shrinkage and selection operator (LASSO) was used to construct nFRGs. In addition, the analyses involved in prognoses, molecular function, stemness indices, somatic mutation, responses to immunologic therapy, efficacy of transcatheter arterial chemoembolization (TACE) therapy and drug sensitivity were performed using diverse packages of R 4.1.3 between the low- and high-risk groups. The nFRGs included seven ferroptosis-related genes. Our results showed that nFRGs was an independent risk factor for prognoses of HCC patients, and HCC patients in the high-risk group presented with worse prognosis. Compared with the results of other studies, nFRGs was superior to other promising signatures in predicting prognoses of patients with HCC. In addition, most of the enriched pathways of differentially expressed genes (DEGs) between these subgroups were related to immune features. The molecular functions, genetic mutation and mRNAsi were varied between the high- and low-risk groups. Moreover, we observed significant immunosuppression state in the high-risk group. Patients in the high-risk group might benefit from immunotherapy, whereas patients in the low-risk group may be susceptible to TACE therapy. Finally, five sensitive drugs and four sensitive drugs were screened for patients in the high- and low-risk groups, respectively. nFRGs may served as a novel biomarker of prognosis and aid in personalized therapeutic strategies for patients with HCC.

12 November 2025 in Cancer Immunology, Immunotherapy
Verified
Journal Article
Open access
PDF file
ZCZhao Chuanbing
Zhao Chuanbing
YLYu Lu
Yu Lu
LHLong He
Long He
YZYunpeng Zhang
Yunpeng Zhang
TYTao Yin
Tao Yin
Matrix stiffness is a defining feature of pancreatic ductal adenocarcinoma (PDAC) and drives malignant progression through mechanisms that remain poorly understood. Using an ensemble machine learning approach, we integrated multiomics data from 886 patients with mechano-biology models to develop a nine-gene matrix stiffness-associated gene signature (MSAGS). MSAGS demonstrated superior prognostic accuracy in independent cohorts, outperforming 87 existing signatures. We identified SLC20A1 within MSAGS as a novel mechano-immunological checkpoint where matrix stiffness activates an SLC20A1-STAT3 positive feedback loop, driving dual immunosuppression via TGF-β1-mediated CD8+ T-cell exclusion and PD-L1-induced T-cell dysfunction. Importantly, targeting SLC20A1 synergized with anti-PD-L1/TGF-beta bispecific antibody (BiTP, Y101D), enhancing tumor suppression and extending survival in orthotopic PDAC models by increasing the infiltration and function of cytotoxic CD8+ T cells. This work establishes MSAGS as a clinically translatable prognostic tool and positions SLC20A1 targeting as a transformative strategy to overcome PDAC immunotherapy resistance, thereby repositioning matrix stiffness as a druggable target. Graphical abstract

16 February 2026 in Experimental Hematology & Oncology
Verified
Journal Article
Open access
PDF file
HZHaoxiang Zhang
Haoxiang Zhang
ZCZhao Chuanbing
Zhao Chuanbing
JCJiaoshun Chen
Jiaoshun Chen
XHXiaoqing Hu
Xiaoqing Hu
JBJianwei Bai
Jianwei Bai
TYTao Yin
Tao Yin
Alterations in extracellular matrix (ECM) architecture and stiffness are hallmarks of aggressive pancreatic cancer progression. However, the mechanisms by

20 April 2023 in BMC Medical Genomics
Verified
Journal Article
Open access
PDF file
RDRuili Ding
Ruili Ding
ZCZhao Chuanbing
Zhao Chuanbing
YJYixin Jing
Yixin Jing
RCRong Chen
Rong Chen
QMQing-tao Meng
Qing-tao Meng
Background: Hepatocellular carcinoma (HCC) remains a global health threat. Finding a novel biomarker for assessing the prognosis and new therapeutic targets is vital to treating this patient population. Our study aimed to explore the contribution of basement membrane-related regulators (BMR) to prognostic assessment and therapeutic response prediction in HCC.Material and methods: The RNA sequencing and clinical information of HCC were downloaded from TCGA-LIHC, ICGC-JP, GSE14520, GSE104580, and CCLE datasets. The BMR signature was created by the Least Absolute Shrinkage and Selection Operator (LASSO) algorithm and used to separate HCC patients into low- and high-risk groups. We conducted analyses using various R 4.1.3 software packages to compare prognoses and responses to immunotherapy, transcatheter arterial chemoembolization (TACE), and chemotherapeutic drugs between the groups. Additionally, stemness indices, molecular functions, and somatic mutation analyses were further explored in these subgroups.Results: The BMR signature included 3 basement membrane-related genes (CTSA, P3H1, and ADAM9). We revealed that BMR signature was an independent risk contributor to poor prognosis in HCC, and high-risk group patients presented shorter overall survival. We discovered that patients in the high-risk group might be responsive to immunotherapy, while patients in the low-risk group may be susceptible to TACE therapy. Over 300 agents were screened to identify effective drugs for the two subgroups.Conclusion: Overall, basement membrane-related regulators represent novel biomarkers in HCC for assessing prognosis, response to immunotherapy, the effectiveness of TACE therapy, and drug susceptibility.